Could Jaguar Health Inc (NASDAQ:JAGX) See a Reversal After Less Sellers Came In?

Jaguar Health, Inc. (NASDAQ:JAGX) Logo

The stock of Jaguar Health Inc (NASDAQ:JAGX) registered a decrease of 26.93% in short interest. JAGX’s total short interest was 99,300 shares in October as published by FINRA. Its down 26.93% from 135,900 shares, reported previously. With 321,400 shares average volume, it will take short sellers 0 days to cover their JAGX’s short positions. The short interest to Jaguar Health Inc’s float is 0.49%.

The stock decreased 6.65% or $0.0501 during the last trading session, reaching $0.703. About 904,239 shares traded. Jaguar Health, Inc. (NASDAQ:JAGX) has declined 97.61% since October 12, 2018 and is downtrending. It has underperformed by 97.61% the S&P500.

Napo Pharmaceuticals, Inc., a human health company, focuses on developing and commercializing novel gastrointestinal prescription products from plants. The company has market cap of $4.29 million. The Company’s products include Mytesi, an FDA approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It currently has negative earnings. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc.

More notable recent Jaguar Health, Inc. (NASDAQ:JAGX) news were published by: which released: “66 Biggest Movers From Yesterday – Benzinga” on June 12, 2019, also with their article: “Jaguar Health files for equity offering; shares down 8% premarket – Seeking Alpha” published on July 15, 2019, published: “Jaguar Health down 11% in 1:70 reverse split – Seeking Alpha” on June 06, 2019. More interesting news about Jaguar Health, Inc. (NASDAQ:JAGX) were released by: and their article: “23 Healthcare Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” published on September 25, 2019 as well as‘s news article titled: “Jaguar Health up 60% premarket on NIAID support for cholera candidate – Seeking Alpha” with publication date: June 11, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.